Streptozotocin-induced type 1 diabetes in rodents as a model for studying mitochondrial mechanisms of diabetic β cell glucotoxicity

Diabetes, Metabolic Syndrome and Obesity

Volumn 8, Issue , 2015, Pages 181-188

  Wu, Jinzi ^a   Yan, Liang Jun ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Diabetes; Glucotoxicity; Mitochondria; Redox imbalance; Streptozotocin; cell

Indexed keywords

ADENOSINE TRIPHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ACUTE TOXICITY; CELL REGENERATION; CELL SURVIVAL; CYTOTOXICITY; DNA ALKYLATION; DNA METHYLATION; GLUCOSE OXIDATION; GLUCOTOXICITY; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NONHUMAN; NUCLEOTIDE METABOLISM; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; REVIEW; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS;

EID: 84936942895     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S82272     Document Type: Review

References (71)

1. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008;29(3):351-366.
2. Korsgren O, Jansson L, Sandler S, Andersson A. Hyperglycemia-induced B cell toxicity. The fate of pancreatic islets transplanted into diabetic mice is dependent on their genetic background. J Clin Invest. 1990;86(6): 2161-2168.
3. Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143(2):339-342.
4. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50(6):537-546.
5. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008;51(2):216-226.
6. Rakieten N, Rakieten ML, Nadkarni MR. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep. 1963; 29:91-98.
7. Gajdosik A, Gajdosikova A, Stefek M, Navarova J, Hozova R. Streptozotocin-induced experimental diabetes in male Wistar rats. Gen Physiol Biophys. 1999;18:54-62.
8. Ghasemi A, Khalifi S, Jedi S. Streptozotocin-nicotinamide-induced rat model of type 2 diabetes (review). Acta Physiol Hung. 2014;101(4): 408-420.
9. Junod A, Lambert AE, Stauffacher W, Renold AE. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest. 1969;48(11):2129-2139.
10. Yin D, Tao J, Lee DD, et al. Recovery of islet beta-cell function in streptozotocin-induced diabetic mice: an indirect role for the spleen. Diabetes. 2006;55(12):3256-3263.
11. Wu MS, Liang JT, Lin YD, Wu ET, Tseng YZ, Chang KC. Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetes. Br J Pharmacol. 2008;154(4):758-764.
12. Szkudelski T. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med (Maywood). 2012;237(5):481-490.
13. Skovso S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig. 2014;5(4):349-358.
14. Patil MA, Suryanarayana P, Putcha UK, Srinivas M, Reddy GB. Evaluation of neonatal streptozotocin induced diabetic rat model for the development of cataract. Oxid Med Cell Longev. 2014;2014: 463264.
15. Portha B, Blondel O, Serradas P, et al. The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabete Metab. 1989;15(2):61-75.
16. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005; 52(4):313-320.
17. Kumar S, Vasudeva N, Sharma S. GC-MS analysis and screening of antidiabetic, antioxidant and hypolipidemic potential of Cinnamomum tamala oil in streptozotocin induced diabetes mellitus in rats. Cardiovasc Diabetol. 2012;11:95.
18. Vavra JJ, Deboer C, Dietz A, Hanka LJ, Sokolski WT. Streptozotocin, a new antibacterial antibiotic. Antibiot Annu. 1959;7:230-235.
19. Johansson EB, Tjalve H. Studies on the tissue-disposition and fate of [14C]streptozotocin with special reference to the pancreatic islets. Acta Endocrinol. 1978;89(2):339-351.
20. Bouwens L, Rooman I. Regulation of pancreatic beta-cell mass. Physiol Rev. 2005;85(4):1255-1270.
21. 14Streptozotocin and its distribution and excretion in the rat. Biochem J. 1974;142:673-683.
22. Eleazu CO, Eleazu KC, Chukwuma S, Essien UN. Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. J Diabetes Metab Disord. 2013;12(1):60.
23. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology. 2007;12(3):261-266.
24. Wei M, Ong L, Smith MT, et al. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ. 2003;12(1):44-50.
25. Yan LJ. Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res. 2014;2014:137919.
26. Issad T, Masson E, Pagesy P. O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab. 2010;36(6 pt 1):423-435.
27. Naruse K, Rask-Madsen C, Takahara N, et al. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes. 2006;55(3):691-698.
28. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993;42(6):801-813.
29. Queisser MA, Yao D, Geisler S, et al. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes. 2010;59(3):670-678.
30. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J. 1987;245(1):243-250.
31. Leibowitz G, Kaiser N, Cerasi E. beta-Cell failure in type 2 diabetes. J Diabetes Investig. 2011;2(2):82-91.
32. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004;279(41):42351-42354.
33. Maechler P, Wollheim CB. Role of mitochondria in metabolism-secretion coupling of insulin release in the pancreatic beta-cell. Biofactors. 1998;8(3-4):255-262.
34. Malmgren S, Nicholls DG, Taneera J, et al. Tight coupling between glucose and mitochondrial metabolism in clonal beta-cells is required for robust insulin secretion. J Biol Chem. 2009;284(47):32395-32404.
35. Sekine N, Cirulli V, Regazzi R, et al. Low lactate dehydrogenase and high mitochondrial glycerol phosphate dehydrogenase in pancreatic beta-cells. Potential role in nutrient sensing. J Biol Chem. 1994;269(7): 4895-4902.
36. Wiederkehr A, Wollheim CB. Minireview: implication of mitochondria in insulin secretion and action. Endocrinology. 2006;147(6): 2643-2649.
37. Schuit F, De Vos A, Farfari S, et al. Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in beta cells. J Biol Chem. 1997;272(30):18572-18579.
38. Maechler P. Mitochondrial function and insulin secretion. Mol Cell Endocrinol. 2013;379(1-2):12-18.
39. Maechler P, Carobbio S, Rubi B. In beta-cells, mitochondria integrate and generate metabolic signals controlling insulin secretion. Int J Biochem Cell Biol. 2006;38(5-6):696-709.
40. Maechler P. Mitochondrial signal transduction in pancreatic beta-cells. Best Pract Res Clin Endocrinol Metab. 2012;26(6):739-752.
41. Zou CY, Gong Y, Liang J. Metabolic signaling of insulin secretion by pancreatic beta-cell and its derangement in type 2 diabetes. Eur Rev Med Pharmacol Sci. 2014;18(15):2215-2227.
42. Satin LS, Butler PC, Ha J, Sherman AS. Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes. Mol Aspects Med. In press 2015.
43. Wiederkehr A, Wollheim CB. Mitochondrial signals drive insulin secretion in the pancreatic beta-cell. Mol Cell Endocrinol. 2012;353(1-2): 128-137.
44. Bensellam M, Laybutt DR, Jonas JC. The molecular mechanisms of pancreatic beta-cell glucotoxicity: recent findings and future research directions. Mol Cell Endocrinol. 2012;364(1-2):1-27.
45. Teodoro JS, Rolo AP, Palmeira CM. The NAD ratio redox paradox: why does too much reductive power cause oxidative stress? Toxicol Mech Methods. 2013;23(5):297-302.
46. Luo X, Li R, Yan L-J. Roles of pyruvate, NADH, and mitochondrial complex I in redox balance and imbalance in β cell function and dysfunction. J Diabetes Res. 2015.
47. Gomes A, Vedasiromoni JR, Das M, Sharma RM, Ganguly DK. Anti-hyperglycemic effect of black tea (Camellia sinensis) in rat. J Ethnopharmacol. 1995;45(3):223-226.
48. Mossman BT, Ireland CM, Filipak M, LeDoux S, Wilson GL. Comparative interactions of streptozotocin and chlorozotocin with DNA of an insulin-secreting cell line (RINr). Diabetologia. 1986;29(3):186-191.
49. Pettepher CC, LeDoux SP, Bohr VA, Wilson GL. Repair of alkali-labile sites within the mitochondrial DNA of RINr 38 cells after exposure to the nitrosourea streptozotocin. J Biol Chem. 1991;266(5):3113-3117.
50. Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev. 1970;22(4):485-518.
51. Kullin M, Li Z, Hansen JB, Bjork E, Sandler S, Karlsson FA. K(ATP) channel openers protect rat islets against the toxic effect of streptozotocin. Diabetes. 2000;49(7):1131-1136.
52. Matsuda M, Kawasaki F, Mikami Y, et al. Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes. Eur J Pharmacol. 2002;453(1): 141-148.
53. Grossman EJ, Lee DD, Tao J, et al. Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PLoS One. 2010;5(1):e8749.
54. Rodrigues B, Poucheret P, Battell ML, Mcneill JH. Streptozotocin-induced diabetes: Induction, mechanism(s), and dose dependency. In: McNeill JH, editor. Experimental Models of Diabetes. Boca Raton: CRC Press; 1999:3-18.
55. Kozuka C, Sunagawa S, Ueda R, et al. Gamma-oryzanol protects pancreatic beta-cells against endoplasmic reticulum stress in male mice. Endocrinology. 2015;156(4):1242-1250.
56. Marchand KC, Arany EJ, Hill DJ. Effects of atorvastatin on the regeneration of pancreatic {beta}-cells after streptozotocin treatment in the neonatal rodent. Am J Physiol Endocrinol Metab. 2010;299(1): E92-E100.
57. Hamming NA, Reynolds WA. DNA synthesis in pancreatic islet and acinar cells in rats with streptozotocin-induced diabetes. Horm Metab Res. 1977;9(2):114-116.
58. Ding Y, Zhang Z, Dai X, et al. Grape seed proanthocyanidins ameliorate pancreatic beta-cell dysfunction and death in low-dose streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats partially by regulating endoplasmic reticulum stress. Nutr Metab. 2013;10:51.
59. Chanpoo M, Petchpiboonthai H, Panyarachun B, Anupunpisit V. Effect of curcumin in the amelioration of pancreatic islets in streptozotocin-induced diabetic mice. J Med Assoc Thai. 2010;93(Suppl 6): S152-S159.
60. Ku CR, Lee HJ, Kim SK, Lee EY, Lee MK, Lee EJ. Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic beta-cell and the cleavage of poly (ADP-ribose) polymerase. Endocr J. 2012;59(2):103-109.
61. Parveen K, Ishrat T, Malik S, Kausar MA, Siddiqui WA. Modulatory effects of Pycnogenol in a rat model of insulin-dependent diabetes mellitus: biochemical, histological, and immunohistochemical evidences. Protoplasma. 2013;250(1):347-360.
62. Kannadhasan R, Ashwini Anjana AJ. Phytochemical and antioxidant activity of polyherbal hydroethanolic extract in streptozotocin induced β cell destruction in rats. Int J Pharm Sci Drug Res. 2012;4(1): 25-30.
63. Erejuwa OO, Sulaiman SA, Wahab MS, Sirajudeen KN, Salleh MS, Gurtu S. Antioxidant protection of Malaysian tualang honey in pancreas of normal and streptozotocin-induced diabetic rats. Ann Endocrinol. 2010;71(4):291-296.
64. Niture NT, Ansari AA, Naik SR. Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers. Indian J Exp Biol. 2014;52(7): 720-727.
65. Mellado-Gil JM, Aguilar-Diosdado M. High glucose potentiates cytokine- and streptozotocin-induced apoptosis of rat islet cells: effect on apoptosis-related genes. J Endocrinol. 2004;183(1):155-162.
66. Fujimoto H, Hirase T, Miyazaki Y, et al. IL-27 inhibits hyperglycemia and pancreatic islet inflammation induced by streptozotocin in mice. Am J Pathol. 2011;179(5):2327-2336.
67. O'Brien BA, Harmon BV, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol. 1996;178(2):176-181.
68. Zhang M, Lv XY, Li J, Xu ZG, Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res. 2008;2008:704045.
69. Takada J, Machado MA, Peres SB, et al. Neonatal streptozotocin-induced diabetes mellitus: a model of insulin resistance associated with loss of adipose mass. Metabolism. 2007;56(7):977-984.
70. Larsen MO. Beta-cell function and mass in type 2 diabetes. Dan Med Bull. 2009;56(3):153-164.
71. Deeds MC, Anderson JM, Armstrong AS, et al. Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Lab Anim. 2011;45(3):131-140.